Company Overview
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs , including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma, G12D protein for the treatment of cancers with the G12D mutation, comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer. In addition, the company develops Bavdegalutamide (ARV-110) and Luxdegalutamide (ARV-766), investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer. It has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
Why Investors Should Care
Revenue has grown at a 65.9% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $262.60M (-0.3% YoY); net profit $-80.80M.
- Trailing 12 Months Year-on-year growth — revenue -91.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 65.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 65.94% |
| 1 Year: | -91.70% |
Stock Price Performance
| 1 Year: | +5.21% |
| 6 Months: | -31.85% |
| 3 Months: | -24.73% |
| 1 Month: | +9.23% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)50.05 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 65.9% over 5 years.
CONS
- Trading 40.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ARVN Arvinas, Inc. R2K | 8.28 | -2.55 | $534.24M | 0.00% | -20.59% | -42.28% | 65.94% | - |
| 2 | LLY Eli Lilly and Company SPX | 1,156.63 | 41.13 | $1.03T | 0.60% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 247.02 | 28.66 | $594.63B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.11 | 119.08 | $431.29B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 418.52 | 31.54 | $380.08B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 123.61 | 34.82 | $305.29B | 2.82% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 168.37 | 26.10 | $261.12B | 1.87% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 535.29 | 29.40 | $198.93B | 0.35% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 358.32 | 24.92 | $193.39B | 2.80% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 4.00M | - | - | - | 6.20M | - | - | 5.50M | - | - | - | - | - | - | - | - | - | - | - | - | 188.80M | 22.40M | 41.90M | 9.50M | 15.60M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 117.40M | 93.90M | 85.70M | 84.10M | 79.40M |
| Operating Income | -6.32M | -6.72M | -6.41M | -5.31M | -4.28M | -8.52M | -14.06M | -16.94M | -15.81M | -18.42M | 5.50M | -22.79M | -23.41M | -26.48M | -31.75M | -41.70M | -51.90M | -47.30M | -57.70M | -65.80M | -64.30M | -87.70M | -74.60M | -73.90M | -83.30M | -48.50M | - | - | 71.40M | -71.50M | -43.80M | -74.60M | -63.80M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 72.70M | -70.10M | -42.50M | -73.40M | -62.70M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 83.10M | -61.50M | -34.80M | -67.20M | -57.50M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 200.00K | -300.00K | 300.00K | 200.00K | 100.00K |
| Net Income | -6.25M | -6.68M | -6.40M | -4.73M | -4.15M | -7.85M | -13.39M | -16.09M | -14.40M | -17.16M | -17.68M | -21.05M | -21.74M | -25.23M | -30.82M | -41.00M | -50.30M | -46.80M | -63.40M | -70.00M | -66.20M | -81.90M | -66.60M | -64.00M | -69.40M | -35.20M | - | - | 82.90M | -61.20M | -35.10M | -67.40M | -57.60M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.84 | -1.03 | -0.94 | -1.20 | -1.32 | -1.24 | -1.54 | -1.25 | -1.18 | -0.97 | -0.49 | - | - | 1.14 | -0.84 | -0.48 | -1.10 | -0.90 |
| R&D Expense | 7.06M | 7.82M | 7.22M | 6.69M | 7.14M | 10.34M | 13.15M | 14.56M | 14.19M | 16.00M | 16.59M | 20.41M | 21.73M | 23.42M | 30.01M | 34.90M | 43.00M | 40.60M | 64.00M | 75.30M | 77.50M | 95.30M | 103.40M | 85.90M | 84.30M | 93.70M | 86.90M | - | 90.80M | 68.60M | 64.70M | - | 60.30M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.58M | 14.30M | 18.30M | 21.80M | - | 131.40M | 78.50M | 263.40M | 262.60M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | 394.60M | 480.00M | 513.60M | 381.10M |
| Operating Income | -24.76M | -43.80M | -51.50M | -120.80M | - | -263.20M | -401.50M | -250.20M | -118.50M |
| EBITDA | - | - | - | - | - | -255.00M | -394.80M | -243.60M | -113.30M |
| Interest Expense | - | - | - | - | 100.00K | - | - | - | - |
| Pretax Income | - | - | - | - | - | -251.00M | -363.90M | -198.30M | -80.50M |
| Tax Provision | - | - | - | - | - | 20.90M | 900.00K | 600.00K | 300.00K |
| Net Income | -24.05M | -41.48M | -70.30M | -119.30M | - | -282.50M | -367.30M | -198.90M | -80.80M |
| Diluted EPS | - | - | -2.13 | -3.02 | - | -5.31 | -6.62 | -2.77 | -1.14 |
| R&D Expense | 28.79M | 45.19M | 67.20M | 108.40M | 180.40M | 315.00M | 379.70M | 348.20M | 285.20M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 66.85M | 199.28M | 301.64M | 717.40M | - | 1.27B | 1.30B | 1.09B | 717.90M |
| Current Assets | - | - | - | - | - | - | 1.24B | 1.28B | 1.07B | 700.70M |
| Cash & Equivalents | - | 30.91M | 3.19M | 9.21M | 588.40M | - | 81.30M | 311.70M | 100.50M | 142.90M |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | 1.00M | 0 | 5.70M | 1.00M |
| Total Liabilities | - | 66.60M | 62.61M | 74.96M | 75.20M | - | 703.90M | 644.60M | 529.80M | 284.10M |
| Current Liabilities | - | 17.85M | 22.98M | 32.81M | 49.20M | - | 295.10M | 257.10M | 229.80M | 142.50M |
| Long Term Debt | - | 151.12K | 2.00M | 2.00M | 2.00M | - | 1.00M | 800.00K | 600.00K | 400.00K |
| Total Debt | - | - | - | - | - | - | 5.50M | 3.20M | 9.70M | 8.90M |
| Total Equity | -32.88M | -61.23M | 136.60M | 226.60M | 642.20M | - | 564.90M | 660.00M | 561.60M | 433.80M |
| Shares Outstanding | - | - | - | - | - | - | 53.20M | 68.00M | 68.80M | 73.50M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 5.11M | -16.12M | -40.60M | -89.70M | - | -273.50M | -347.80M | -259.30M | -273.80M |
| Investing Cash Flow | 20.87M | -179.67M | -93.10M | 164.30M | - | 242.80M | 203.50M | 34.70M | 407.60M |
| Financing Cash Flow | -161.36K | 168.06M | 139.70M | 504.60M | - | 4.70M | 374.70M | 7.90M | -91.40M |
| Capital Expenditure | -1.01M | -2.83M | -6.30M | -6.40M | - | -6.80M | -2.90M | -1.80M | -1.90M |
| Free Cash Flow | 4.10M | -18.95M | -46.90M | -96.10M | - | -280.30M | -350.70M | -261.10M | -275.70M |
| Net Change in Cash | - | - | - | - | - | -26.00M | 230.40M | -216.70M | 42.40M |
| Share Buybacks | - | - | - | - | - | - | 0 | 0 | 91.90M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Operating Margin % | -326.7% | -306.3% | -281.4% | -554.1% | - | -200.3% | -511.5% | -95.0% | -45.1% |
| Net Margin % | -317.3% | -290.1% | -384.2% | -547.2% | - | -215.0% | -467.9% | -75.5% | -30.8% |
| ROE % | 39.3% | -30.4% | -31.0% | -18.6% | - | -50.0% | -55.7% | -35.4% | -18.6% |
| ROCE % | -50.5% | -24.8% | -19.2% | -18.1% | - | -27.0% | -38.3% | -29.0% | -20.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 10.54% | 6.80M | $56.22M |
| 2 | Vanguard Portfolio Management LLC | 6.03% | 3.89M | $32.17M |
| 3 | Shaw D.E. & Co., Inc. | 5.64% | 3.64M | $30.09M |
| 4 | Pfizer Inc | 5.36% | 3.46M | $28.60M |
| 5 | Vanguard Capital Management LLC | 4.17% | 2.69M | $22.24M |
| 6 | TCG Crossover Management, LLC | 3.70% | 2.39M | $19.74M |
| 7 | Armistice Capital, LLC | 3.07% | 1.98M | $16.36M |
| 8 | Two Sigma Investments, LP | 2.84% | 1.83M | $15.15M |
| 9 | State Street Corporation | 2.83% | 1.83M | $15.12M |
| 10 | Geode Capital Management, LLC | 2.41% | 1.56M | $12.88M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ARVN
uniQure (QURE) Soars 78.4%: Is Further Upside Left in the Stock?
uniQure (QURE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Rigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant)
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the closing of its license agreement for VEPPANUTM (vepdegestrant), following the early termin…
Twist Bioscience (TWST) Surges 9.3%: Is This an Indication of Further Gains?
Twist Bioscience (TWST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.…
Arvinas Sharpens Pipeline Focus After First PROTAC Approval, Eyes Key Trial Data
Arvinas (NASDAQ:ARVN) management outlined a more selective development strategy at a Jefferies-hosted investor discussion, emphasizing internal investment in neurological and oncology programs where the company believes it can create differ…
Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease
NEW HAVEN, Conn., June 04, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced it has recently joined the LRRK2 Investigative Th…
Arvinas to Present at Jefferies Global Healthcare Conference
NEW HAVEN, Conn., May 29, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in…
ARVN — Frequently Asked Questions
What is the current share price of Arvinas, Inc. (ARVN)?
As of 2026-07-15 16:51 PDT, Arvinas, Inc. (ARVN) trades at $8.28 on NasdaqGS. Its 52-week range is $6.24 to $13.83.
What is the market capitalisation of ARVN?
Arvinas, Inc. (ARVN) has a market capitalisation of $534.24M on NasdaqGS.
What is the P/E ratio of ARVN?
ARVN trades at a trailing price-to-earnings (P/E) ratio of -2.55. The industry average P/E is 25.88. Its price-to-book (P/B) ratio is 1.38.
What is the return on equity (ROE) of ARVN?
ARVN has a return on equity (ROE) of -42.28%. Its return on capital employed (ROCE) is -20.59%.
Is ARVN a good stock to buy?
This page provides a data-driven analysis of Arvinas, Inc. (ARVN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.